

Supplementary Methods


General Information and Materials

All reactions and manipulations were performed in a nitrogen-filled glove box or using standard Schlenk techniques, unless otherwise noted. All anhydrous solvents were purchased from J & K Chemicals or Alfa Chemicals Inc, or used after standard purification procedures. Ni(cod)₂ was purchased from Strem chemicals. Commercialized reagents were used without further purifications. All air sensitive ligands were stored in a nitrogen-filled glove box before use. Chiral ligand intermediates were prepared according to our reported procedures. Tf = trifluoromethylsulfonate, cod = 1,5-cyclooctadiene, PMHS = polymethylhydrosiloxane.


¹H, ³¹P, ¹⁹F and ¹³C NMR data were recorded on a BrukerDRX500, DRX400, NMR Spectrometer with CDCl₃, or CD₃OD as the solvent. ¹H chemical shifts were referenced to CDCl₃ at 7.26 ppm. ¹³C chemical shifts were referenced to CDCl₃ at 77.16 ppm and obtained with ¹H decoupling. ³¹P shifts were referenced to 85% H₃PO₄ in D₂O at 0.0 ppm as external standard and obtained with ¹H decoupling. Multiplicities are abbreviated as follows: singlet (s), doublet (d), triplet (t), quartet (q), doublet-doublet (dd), quintet (quint), septet (sept), multiplet (m), and broad (br). MS was measured on Agilent 5973N (EI), Agilent 1100 Series LC/MSD (ESI) mass spectrometers. Column chromatography was performed with silica gel (200-300 mesh). X-Ray crystallographic analysis data were collected using a Bruker Smart-APEX instrument (CCD detector) or a Bruker Kappa APEX-II instrument (CCD detector). HPLC analyses and purifications were performed on a Agilent LC system with UV/VIS detector using chiralcel columns.

Ligand Synthesis

Chiral ligands **(S)-Me-BIDIME (L2)** and **(S)-BIDIME (L3)** were prepared according to a procedure reported previously in our laboratory¹. All commercial available ligands were purchased from Sigma-Aldrich, Alfa Chemicals, Strem chemicals or J & K Chemicals Inc.




Supplementary Figure 1. Synthesis of Ligand **(S,S)-DI-BI-DIME (L4)**.



(R)-3-(tert-butyl)-4-((tert-butyldiphenylsilyl)oxy)-2H-benzo[d][1,3]oxaphosphole 3-oxide (S2): To a solution of **S1** (2.00 g, 8.84 mmol, 1.0 equiv) and imidazole (1.20 g, 17.68 mmol, 2.0 equiv) in DCM (25 mL) at rt was added TBDPSCI (3.20 g, 11.49 mmol, 1.3 equiv) dropwisely under N₂. After stirring

at rt overnight, the reaction was quenched with water, extracted with DCM, washed with saturated brine, dried with anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: DCM/MeOH 100/1) to afford **S2** as white solid (4.11

g, 99%). **S2**: $[\alpha]_D^{25} = -8.2$ ($c = 1.0$, CHCl_3). ^1H NMR (500 MHz, CDCl_3) δ 7.81 (dd, $J = 7.7$, 1.5 Hz, 2H), 7.81 (dd, $J = 7.7$, 1.5 Hz, 2H), 7.50 – 7.42 (m, 3H), 7.39 – 7.35 (m, 1H), 7.34 – 7.29 (m, 2H), 6.90 (t, $J = 8.2$ Hz, 1H), 6.39 (dd, $J = 8.2$, 1.8 Hz, 1H), 6.02 (dd, $J = 8.1$, 3.5 Hz, 1H), 4.56 (d, $J = 13.7$ Hz, 1H), 4.38 (dd, $J = 13.2$, 10.8 Hz, 1H), 1.32 (d, $J = 16.0$ Hz, 9H), 1.12 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3) δ 166.29 (d, $J = 17.6$ Hz), 157.97 (d, $J = 1.5$ Hz), 135.51 (d, $J = 40.3$ Hz), 135.44 (d, $J = 0.8$ Hz), 132.14 (d, $J = 183.7$ Hz), 130.14 (d, $J = 1.9$ Hz), 128.01 (d, $J = 19.6$ Hz), 113.03 (d, $J = 5.8$ Hz), 106.43 (d, $J = 5.4$ Hz), 104.70 (d, $J = 92.8$ Hz), 65.79 (d, $J = 60.0$ Hz), 34.22 (d, $J = 73.2$ Hz), 26.56, 24.69 (d, $J = 0.8$ Hz), 19.62; ^{31}P NMR (162 MHz, CDCl_3) δ 63.13; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{27}\text{H}_{33}\text{NaO}_3\text{PSi}]^+$: 487.1829; found: 487.1832.



(R)-4-(benzyloxy)-7-bromo-3-(tert-butyl)-2H-benzo[d][1,3]-oxaphosphole


3-oxide (S4): To a solution of **S2** (4.10 g, 8.82 mmol, 1.0 equiv) in DCM (90 mL) at rt was added NBS (1.65 g, 9.27 mmol, 1.05 equiv) under N_2 . After stirring at rt for 4 h, the reaction was quenched with water, extracted with DCM, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under

vacuum. The residue (**S3**) was used without further purification.


To a solution of the above residue (**S3**) in THF (20 mL) at 0 °C was added TBAF (13.3 mL, 13.24 mmol, 1.5 equiv, 1.0 M in THF) and stirred at 0 °C for 5 min. Quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was used without further purification.

To a solution of the above residue and K_2CO_3 (3.66 g, 26.47 mmol, 3.0 equiv) in DMF (50 mL) at 0 °C was added BnBr (1.26 mL, 10.59 mmol, 1.2 equiv) dropwisely under N_2 and stirred at rt overnight. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: DCM/MeOH 50/1) to afford **S4** as light yellow solid (3.3 g, 95%). **S4**: $[\alpha]_D^{25} = -41.9$ ($c = 1.0$, MeOH). ^1H NMR (500 MHz, CDCl_3) δ 7.50 (d, $J = 8.6$ Hz, 1H), 7.44 – 7.38 (m, 2H), 7.37 – 7.31 (m, 2H), 7.31 – 7.26 (m, 1H), 6.44 (dd, $J = 8.7$, 4.5 Hz, 1H), 5.13 (q, $J = 12.0$ Hz, 2H), 4.60 (dd, $J = 14.0$, 3.1 Hz, 1H), 4.48 (dd, $J = 14.0$, 10.6 Hz, 1H), 1.21 (d, $J = 16.6$ Hz, 9H); ^{13}C NMR (126 MHz, CDCl_3) δ 162.23 (d, $J = 16.7$ Hz), 159.61 (d, $J = 2.1$ Hz), 138.97 (d, $J = 1.3$ Hz), 135.48, 128.65, 128.25, 127.41, 106.54 (d, $J = 6.2$ Hz), 105.07 (d, $J = 88.2$ Hz), 98.19 (d, $J = 6.9$ Hz), 70.99, 66.87 (d, $J = 58.4$ Hz), 34.00 (d, $J =$


73.6 Hz), 24.65 (d, $J = 0.8$ Hz); ^{31}P NMR (162 MHz, CDCl_3) δ 65.18; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{18}\text{H}_{21}\text{BrO}_3\text{P}]^+$: 395.0407; found: 395.0406.




(3*R*,3'*R*)-4,4'-bis(benzyloxy)-3,3'-di-*tert*-butyl-2*H*,2'*H*-[7,7'-bibenzo[d][1,3]oxaphosphole] 3,3'-dioxide (S5): **S4** (1.30 g, 3.29 mmol, 1.0 equiv), $\text{Pd}(\text{OAc})_2$ (148 mg, 0.66 mmol, 0.2 equiv), Sphos (567 mg, 1.38 mmol, 0.42 equiv), $(\text{BPin})_2$ (585 mg, 2.30 mmol, 0.7 equiv) and KOAc (968 mg, 9.87 mmol, 3.0 equiv) were dissolved in dioxane/ H_2O (15 mL, 4/1) at rt under N_2 and stirred at 80 °C for 24 h. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: DCM/MeOH 20/1) to afford **S5** as light yellow solid (670 mg, 65%). **S5**: $[\alpha]_{\text{D}}^{25} = -32.7$ ($c = 1.0$, MeOH). ^1H NMR (500 MHz, CDCl_3) δ 7.48 – 7.41 (m, 4H), 7.40 – 7.33 (m, 6H), 7.33 – 7.27 (m, 2H), 6.59 – 6.53 (m, 2H), 5.24 – 5.14 (m, 4H), 4.51 – 4.33 (m, 4H), 1.24 (d, $J = 16.4$ Hz, 18H); ^{13}C NMR (126 MHz, CDCl_3) δ 163.71 (d, $J = 16.5$ Hz), 159.85 (d, $J = 2.0$ Hz), 137.77, 135.99, 128.66, 128.15, 127.45, 115.06 (d, $J = 5.7$ Hz), 104.77 (d, $J = 6.2$ Hz), 103.35 (d, $J = 91.2$ Hz), 70.78, 66.31 (d, $J = 59.3$ Hz), 33.78 (d, $J = 73.7$ Hz), 24.79; ^{31}P NMR (162 MHz, CDCl_3) δ 64.88; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{36}\text{H}_{41}\text{O}_6\text{P}_2]^+$: 631.2373; found: 631.2377.



(3*R*,3'*R*)-3,3'-di-*tert*-butyl-4,4'-dihydroxy-2*H*,2'*H*-[7,7'-bibenzo[d][1,3]oxaphosphole] 3,3'-dioxide (S6): **S5** (825 mg, 1.31 mmol, 1.00 equiv), Pd/C (800 mg, 10%), and MeOH (15 mL) were combined, and the reaction vessel was evacuated and back-filled with hydrogen (1 atm). The reaction mixture was stirred under hydrogen overnight, then filtered over a plug of silica gel topped with Celite (EtOAc eluent) to afford **S6** as white solid (560 mg, 95%). **S6**: $[\alpha]_{\text{D}}^{25} = +12.1$ ($c = 1.0$, MeOH). ^1H NMR (500 MHz, CD_3OD) δ 7.34 (d, $J = 8.3$ Hz, 2H), 6.51 (dd, $J = 8.2, 4.6$ Hz, 2H), 4.69 (dd, $J = 14.3, 3.2$ Hz, 2H), 4.28 (dd, $J = 14.2, 10.7$ Hz, 2H), 1.30 (d, $J = 16.6$ Hz, 18H); ^{13}C NMR (126 MHz, CD_3OD) δ 165.00 (d, $J = 17.0$ Hz), 160.58 (d, $J = 2.3$ Hz), 139.49, 114.58 (d, $J = 5.9$ Hz), 108.90 (d, $J = 6.8$ Hz), 101.68 (d, $J = 94.2$ Hz), 66.76 (d, $J = 60.7$ Hz), 34.41 (d, $J = 74.0$ Hz), 24.82; ^{31}P NMR (162 MHz, CD_3OD) δ 69.13; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{22}\text{H}_{29}\text{O}_6\text{P}_2]^+$: 451.1434; found: 451.1432.




(3*R*,3'*R*)-3,3'-di-*tert*-butyl-3,3'-dioxido-2*H*,2'*H*-[7,7'-bibenzo[d][1,3]oxaphosphole]-4,4'-diyl bis(trifluoromethanesulfonate) (S7): To a solution of **S6** (560 mg, 1.31 mmol, 1.0 equiv) in DCM at rt was added Et₃N (2.2 mL, 15.70 mmol, 12.0 equiv) and PhNTf₂ (3.74 g, 10.47 mmol, 8.0 equiv) under N₂ and then stirred at rt overnight. Then the reaction was quenched with water, extracted with DCM, washed with saturated brine, dried with anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: DCM/MeOH 50/1) to afford **S7** as white solid (735 mg, 78%). **S7**: [α]_D²⁵ = + 15.6 (c = 1.0, CHCl₃). ¹H NMR (500 MHz, CDCl₃) δ 7.52 (d, *J* = 8.4 Hz, 2H), 7.13 (dd, *J* = 8.4, 3.6 Hz, 2H), 4.58 (dd, *J* = 14.1, 1.7 Hz, 2H), 4.48 (dd, *J* = 13.9, 10.9 Hz, 2H), 1.26 (d, *J* = 16.9 Hz, 18H); ¹³C NMR (126 MHz, CDCl₃) δ 163.39 (d, *J* = 16.5 Hz), 149.76, 137.48, 121.04 (d, *J* = 5.1 Hz), 118.58 (q, *J* = 320.8 Hz), 113.75 (d, *J* = 4.7 Hz), 108.45 (d, *J* = 84.8 Hz), 66.54 (d, *J* = 59.1 Hz), 34.47 (d, *J* = 72.1 Hz), 24.08; ³¹P NMR (162 MHz, CDCl₃) δ 63.67; HRMS (ESI) calculated for [M+Na, C₂₄H₂₆F₆NaO₁₀P₂S₂]⁺: 737.0239; found: 737.0240.



(3*R*,3'*R*)-3,3'-di-*tert*-butyl-4,4'-bis(2,6-dimethoxyphenyl)-2*H*,2'*H*-[7,7'-bibenzo[d][1,3]oxaphosphole]-3,3'-dioxide (S8): To a solution of **S7** (735 mg, 1.03 mmol, 1.0 equiv), (2,6-dimethoxyphenyl)boronic acid (1.85 g, 8.23 mmol, 8.0 equiv) and KF (657 mg, 11.3 mmol, 11.0 equiv) in 10 mL superdry dioxane at rt was added Pd₂(dba)₃ (94 mg, 0.10 mmol, 0.1 equiv) and BI-DIME (75 mg, 0.23 mmol, 0.22 equiv) in the glovebox and stirred at 100 °C overnight. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: DCM/MeOH 20/1) to afford **S8** as gray solid (700 mg, 98%). **S8**: [α]_D²⁵ = +48.1 (c = 1.0, MeOH). ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, *J* = 7.6 Hz, 2H), 7.33 (t, *J* = 8.4 Hz, 2H), 6.98 (dd, *J* = 7.6, 3.6 Hz, 2H), 6.69 (d, *J* = 8.4 Hz, 2H), 6.60 (d, *J* = 8.3 Hz, 2H), 4.46 (dd, *J* = 13.8, 0.9 Hz, 2H), 4.36 (dd, *J* = 13.6, 10.4 Hz, 2H), 3.82 (s, 6H), 3.76 (s, 6H), 0.93 (d, *J* = 15.9 Hz, 18H); ¹³C NMR (126 MHz, CDCl₃) δ 162.43 (d, *J* = 19.3 Hz), 158.81, 157.61, 137.91 (d, *J* = 5.8 Hz), 135.58, 130.13, 125.08 (d, *J* = 9.2 Hz), 121.37 (d, *J* = 6.4 Hz), 117.30 (d, *J* = 1.9 Hz), 114.63 (d, *J* = 91.6 Hz), 104.52, 103.19, 65.22 (d, *J* = 60.9 Hz), 56.08,

55.52, 33.80 (d, $J = 71.6$ Hz), 23.81; ^{31}P NMR (162 MHz, CDCl_3) δ 62.75; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{38}\text{H}_{45}\text{O}_8\text{P}_2]^+$: 691.2584; found: 691.2583.




(3*S*,3'*S*)-3,3'-di-*tert*-butyl-4,4'-bis(2,6-dimethoxyphenyl)-2,2',3,3'-tetrahydro-7,7'-bibenz -o[d]- [1,3]oxaphosphole [(*S,S*)-DI-BI-DIME (L4**)]:**


To a solution of **S8** (680 mg, 0.98 mmol, 1.0 equiv) in THF (20 mL) at room temperature was added polymethylhydrosiloxane (PMHS, 5.4 g) and titanium isopropoxide (2.3 mL, 7.88 mmol, 8.0 equiv). The mixture was stirred at reflux under nitrogen for 12 h and then distilled under vacuum to remove most of THF. To the residue was charged carefully with 30% degassed NaOH solution (30 mL). Gas was released during the addition.

Extracted with degassed Et_2O , dried with anhydrous Na_2SO_4 , filtered, concentrated under vacuum, and passed through a neutral alumina plug (Et_2O) to provide the desired product (**(*S,S*)-DI-BI-DIME (**L4**)**) as white solid (610 mg, 90%). **L4**: $[\alpha]_{\text{D}}^{25} = +47.1$ ($c = 1.0$, CHCl_3). ^1H NMR (500 MHz, CDCl_3) δ 7.54 (d, $J = 7.7$ Hz, 2H), 7.31 (t, $J = 8.3$ Hz, 2H), 6.96 – 6.90 (m, 2H), 6.68 (d, $J = 8.4$ Hz, 2H), 6.61 (d, $J = 8.4$ Hz, 2H), 4.82 (dd, $J = 12.6, 1.4$ Hz, 2H), 4.51 (dd, $J = 24.7, 12.5$ Hz, 2H), 3.79 (s, 6H), 3.73 (s, 6H), 0.81 (d, $J = 12.0$ Hz, 18H); ^{13}C NMR (126 MHz, CDCl_3) δ 160.63, 158.04, 157.37, 137.40 (d, $J = 18.4$ Hz), 132.05, 129.03, 125.27 (d, $J = 12.8$ Hz), 123.66 (d, $J = 4.5$ Hz), 120.51, 120.01, 104.56, 103.70, 70.19 (d, $J = 26.1$ Hz), 55.96 (d, $J = 1.7$ Hz), 55.47, 31.10 (d, $J = 18.6$ Hz), 26.74 (d, $J = 14.5$ Hz); ^{31}P NMR (162 MHz, CDCl_3) δ – 6.93; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{38}\text{H}_{45}\text{O}_6\text{P}_2]^+$: 659.2686; found: 659.2687.


Substrate Synthesis



Supplementary Figure 2. General procedure for substrate **1a**




4-Methyl-N-(3-phenylprop-2-yn-1-yl)benzenesulfonamide (S9). *Tert*-butyl tosylcarbamate (17.7 g, 65.3 mmol, 1.0 equiv) and K_2CO_3 (13.5 g, 97.9 mmol, 1.5 equiv) were dissolved in 65 mL DMF and stirred at rt for 4 h. Then (3-bromoprop-1-yn-1-yl)benzene² (14.0 g, 71.8 mmol, 1.1 equiv) was added to the above solution and stirred at rt for 10 h. The reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was dissolved in 60 mL DCM and 20 mL CF_3COOH and stirred at rt overnight. The reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was recrystallized with hexane/EtOAc to afford **S9** as white solid (17.5 g, 94%). **S9**: ^1H NMR (400 MHz, CDCl_3) δ 7.85 – 7.78 (m, 2H), 7.32 – 7.27 (m, 3H), 7.26 – 7.20 (m, 2H), 7.17 – 7.09 (m, 2H), 4.63 (t, J = 5.8 Hz, 1H), 4.08 (d, J = 6.1 Hz, 2H), 2.36 (s, 3H); ESI-MS: m/z 286.2 $[\text{M}+\text{H}]^+$. The ^1H NMR spectra and ESI-MS are in agreement with those reported in the literature.³




4-Methyl-N-(2-oxo-2-phenylethyl)-N-(3-phenylprop-2-yn-1-yl)-benzenesulfonamide (1a). To a solution of **S2** (5.0 g, 17.5 mmol, 1.0 equiv), 2-bromo-1-phenylethan-1-one (3.7 g, 18.4 mmol, 1.05 equiv), Bu_4NI (647.2 mg, 1.75 mmol, 0.1 equiv) in 35 mL DMF at 0 $^\circ\text{C}$ was added K_2CO_3 (3.6 g, 26.3 mmol, 1.5 equiv) and stirred at 0 $^\circ\text{C}$ for 1 h. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was recrystallized with hexane/EtOAc to afford **1a** as white solid (6.0 g, 85%). **1a**: ^1H NMR (500 MHz, CDCl_3) δ 8.01 – 7.95 (m, 2H), 7.84 – 7.79 (m, 2H), 7.63 – 7.57 (m, 1H), 7.51 – 7.45 (m, 2H), 7.33 – 7.26 (m, 3H), 7.25 – 7.19 (m, 2H), 7.12 – 7.07 (m, 2H), 4.81 (s, 2H), 4.49 (s, 2H), 2.39 (s, 3H); ^{13}C NMR (126

MHz, CDCl₃) δ 193.46, 143.90, 136.12, 135.00, 133.92, 131.69, 129.79, 128.92, 128.64, 128.24, 128.22, 127.80, 122.07, 86.33, 81.67, 51.99, 38.41, 21.60; ESI-MS: m/z 404.3 [M+H]⁺. The ¹H, ¹³C NMR spectra and ESI-MS are in agreement with those reported in the literature.⁴


Preparations of **1b-i** were carried out according to a procedure similar to that for the synthesis of **1a** from corresponding α -bromoketones.




1b: white solid, 92% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.01 – 7.95 (m, 2H), 7.84 – 7.78 (m, 2H), 7.32 – 7.26 (m, 3H), 7.25 – 7.20 (m, 2H), 7.13 – 7.07 (m, 2H), 6.97 – 6.91 (m, 2H), 4.75 (s, 2H), 4.47 (s, 2H), 3.87 (s, 3H), 2.38 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 191.95, 164.15, 143.87, 136.20, 131.74, 130.67, 129.79, 128.62, 128.25, 128.07, 127.87, 122.20, 114.12, 86.28, 81.79, 55.67, 51.75, 38.42, 21.63; HRMS (ESI) calculated for [M+Na, C₂₅H₂₃NNaO₄S]⁺: 456.1240; found: 456.1244.




1c: white powder, 80% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.08 – 8.01 (m, 2H), 7.85 – 7.77 (m, 2H), 7.33 – 7.21 (m, 5H), 7.19 – 7.06 (m, 4H), 4.76 (s, 2H), 4.47 (s, 2H), 2.39 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 192.08, 166.19 (d, J = 256.1 Hz), 144.03, 135.93, 131.69, 131.45 (d, J = 3.0 Hz), 131.08 (d, J = 9.4 Hz), 129.83, 128.71, 128.27, 127.84, 122.03, 116.11 (d, J = 22.0 Hz), 86.46, 81.52, 52.09, 38.50, 21.61; HRMS (ESI) calculated for [M+Na, C₂₄H₂₀FNNaO₃S]⁺: 444.1040; found: 444.1042.




1d: white powder, 73% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.96 – 7.92 (m, 2H), 7.82 – 7.78 (m, 2H), 7.47 – 7.42 (m, 2H), 7.33 – 7.26 (m, 3H), 7.25 – 7.20 (m, 2H), 7.13 – 7.06 (m, 2H), 4.74 (s, 2H), 4.45 (s, 2H), 2.38 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 192.57, 144.07, 140.45, 135.88, 133.33, 131.71, 129.86, 129.77, 129.28, 128.74, 128.29, 127.85, 122.01, 86.52, 81.48, 52.19, 38.53, 21.64; HRMS (ESI) calculated for [M+Na, C₂₄H₂₀ClNNaO₃S]⁺: 460.0745; found: 460.0745.




1e: white powder, 64% yield. ^1H NMR (500 MHz, CDCl_3) δ 8.14 – 8.08 (m, 2H), 7.84 – 7.79 (m, 2H), 7.76 – 7.71 (m, 2H), 7.35 – 7.21 (m, 5H), 7.12 – 7.06 (m, 2H), 4.79 (s, 2H), 4.46 (s, 2H), 2.40 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 193.03, 144.18, 137.70, 135.71, 135.04 (q, $J = 32.6$ Hz), 131.68, 129.90, 128.80, 128.75, 128.30, 127.85, 125.96 (q, $J = 3.6$ Hz), 123.56 (d, $J = 272.8$ Hz), 121.91, 86.66, 81.35, 52.58, 38.63, 21.61; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{25}\text{H}_{20}\text{F}_3\text{NNaO}_3\text{S}]^+$: 494.1008; found: 494.1009.




1f: light yellow solid, 92% yield. ^1H NMR (500 MHz, CDCl_3) δ 7.85 – 7.77 (m, 2H), 7.59 – 7.54 (m, 1H), 7.54 – 7.48 (m, 1H), 7.41 – 7.36 (m, 1H), 7.33 – 7.26 (m, 3H), 7.25 – 7.19 (m, 2H), 7.17 – 7.07 (m, 3H), 4.79 (s, 2H), 4.48 (s, 2H), 3.85 (s, 3H), 2.39 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 193.39, 160.01, 143.92, 136.29, 136.10, 131.71, 129.93, 129.81, 128.66, 128.25, 127.81, 122.08, 120.74, 120.53, 112.49, 86.36, 81.65, 55.62, 52.16, 38.42, 21.62; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{25}\text{H}_{23}\text{NNaO}_4\text{S}]^+$: 456.1240; found: 456.1242.




1g: light yellow solid, 86% yield. ^1H NMR (500 MHz, CDCl_3) δ 7.83 – 7.77 (m, 3H), 7.54 – 7.47 (m, 1H), 7.31 – 7.26 (m, 3H), 7.25 – 7.20 (m, 2H), 7.15 – 7.10 (m, 2H), 7.04 – 6.95 (m, 2H), 4.83 (s, 2H), 4.51 (s, 2H), 3.91 (s, 3H), 2.38 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 194.97, 159.14, 143.54, 136.72, 134.67, 131.65, 130.99, 129.60, 128.51, 128.23, 127.76, 125.52, 122.36, 121.05, 111.67, 85.83, 82.38, 56.11, 55.73, 38.43, 21.60; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{25}\text{H}_{23}\text{NNaO}_4\text{S}]^+$: 456.1240; found: 456.1243.




1h: light yellow solid, 79% yield. ^1H NMR (500 MHz, CDCl_3) δ 8.27 – 8.21 (m, 1H), 8.06 (s, 1H), 7.72 (d, $J = 8.2$ Hz, 2H), 7.27 – 7.20 (m, 3H), 7.19 – 7.14 (m, 3H), 7.13 – 7.07 (m, 2H), 6.99 – 6.93 (m, 2H), 4.42 (s, 2H), 4.35 (s, 2H), 3.74 (s, 3H), 2.25 (s, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 188.54, 143.99, 137.30, 136.83, 135.72, 131.72, 129.78, 128.52, 128.17, 127.96, 126.72, 123.74, 123.06, 122.63, 122.26, 113.99, 109.86, 86.41, 81.51, 53.34, 38.55, 33.83, 21.59; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{27}\text{H}_{25}\text{N}_2\text{O}_3\text{S}]^+$: 457.1580; found: 457.1582.




1i: white solid, 79% yield. ^1H NMR (500 MHz, CDCl_3) δ 7.79 – 7.74 (m, 2H), 7.32 – 7.24 (m, 5H), 7.17 – 7.12 (m, 2H), 4.45 (s, 2H), 4.40 (s, 2H), 2.39 (s, 3H), 1.18 (s, 9H); ^{13}C NMR (126 MHz, CDCl_3) δ 208.92, 143.74, 136.42, 131.68, 129.73, 128.70, 128.34, 127.68, 122.16, 86.11, 81.88, 49.72, 43.64, 37.85, 26.48, 21.60; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{20}\text{H}_{25}\text{NNaO}_3\text{S}]^+$: 406.1447; found: 406.1447.




Supplementary Figure 3. Synthetic procedure of substrate **1j**



4-Methyl-N-(2-oxo-2-phenylethyl)-N-(pent-2-yn-1-yl)benzenesulfonamide (1j). To a solution of 4-methyl-N-(2-oxo-2-phenylethyl)benzenesulfonamide⁵ (1.0 g, 3.46 mmol, 1.0 equiv), 1-bromopent-2-yne (0.48 mL, 4.50 mmol, 1.3 equiv), Bu_4NI (129 mg, 0.35 mmol, 0.1 equiv) in 10 mL DMF at 0 °C was added K_2CO_3 (1.1 g, 7.85 mmol, 2.5 equiv) under N_2 , and stirred at 0 °C for 2 h. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified by column chromatography (eluent: PE/EA 10/1) to afford **1j** as white solid (1.0 g, 82% yield). **1j**: ^1H NMR (500 MHz, CDCl_3) δ 7.96 (d, J = 7.3 Hz, 2H), 7.77 (d, J = 8.2 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.47 (t, J = 7.7 Hz, 2H), 7.31 (d, J = 8.0 Hz, 2H), 4.74 (s, 2H), 4.21 (s, 2H), 2.42 (s, 3H), 1.94 (tq, J = 7.5, 2.0 Hz, 2H), 0.90 (t, J = 7.5 Hz, 3H); ^{13}C NMR (126 MHz, CDCl_3) δ 193.62, 143.67, 136.29, 135.10, 133.82, 129.61, 128.88, 128.18, 127.81, 88.45, 71.81, 51.80, 38.04, 21.64, 13.56, 12.27; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{20}\text{H}_{21}\text{NNaO}_3\text{S}]^+$: 378.1134; found: 378.1138.




Supplementary Figure 4. Synthetic procedure of substrate **1k**




1,1,1-Trifluoro-N-(2-oxo-2-phenylethyl)methanesulfonamide (S10):

2-Bromo-1-phenylethan-1-one (2.7 g, 13.4 mmol, 1.0 equiv), Trifluoromethanesulfonamide (4.0 g, 26.8 mmol, 2.0 equiv), and K_2CO_3 (3.7 g, 26.8 mmol, 2.0 equiv) were dissolved in 100 mL MeCN, and heated to reflux for 1 h. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified through column chromatography (hexane/EtOAc 30/1) to afford **S10** as white solid (3.8 g, 75%). **S10**: 1H NMR (500 MHz, $CDCl_3$) δ 7.98 – 7.91 (m, 2H), 7.71 – 7.64 (m, 1H), 7.58 – 7.49 (m, 2H), 6.24 (s, 1H), 4.78 (s, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 191.54, 135.10, 133.30, 129.32, 128.19, 119.81 (q, $J = 320.9$ Hz), 49.64; MALDI-TOF-HR-MS calculated for $[M+H, C_9H_9F_3NO_3S]^+$: m/z 268.0250; found: 268.0247.




1k: To a solution of **S2** (300 mg, 1.12 mmol, 1.00 equiv), (3-bromoprop-1-yn-1-yl)benzene (241 mg, 1.23 mmol, 1.10 equiv), Bu_4NI (42 mg, 0.11 mmol, 0.10 equiv) in 2.5 mL DMF at 0 °C was added K_2CO_3 (171 mg, 1.23 mmol, 1.10 equiv) and stirred at 0 °C for 1 h. Then the reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried


with anhydrous Na_2SO_4 , filtered, and concentrated under vacuum. The residue was purified through column chromatography (hexane/EtOAc 50/1) to afford **1k** as white solid (370 mg, 86%). **1k**: 1H NMR (500 MHz, $CDCl_3$) δ 8.00 – 7.94 (m, 2H), 7.69 – 7.62 (m, 1H), 7.56 – 7.49 (m, 2H), 7.42 – 7.27 (m, 5H), 5.05 (s, 2H), 4.67 (s, 2H); ^{13}C NMR (126 MHz, $CDCl_3$) δ 191.55, 134.50, 134.20, 131.96, 129.22, 129.18, 128.53, 128.09, 121.64, 119.91 (q, $J = 322.3$ Hz), 87.12, 80.73, 52.32, 39.89; HRMS (ESI) calculated for $[M+Na, C_{18}H_{14}F_3NNaO_3S]^+$: 404.0539; found: 404.0541.




Supplementary Figure 5. Synthetic procedure of substrate **1l**




1l: (*N*-benzyl-3-phenylprop-2-yn-1-amine⁶ was used), white solid, 77% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.96 – 7.89 (m, 2H), 7.53 – 7.47 (m, 1H), 7.42 – 7.31 (m, 6H), 7.29 – 7.17 (m, 6H), 4.01 (s, 2H), 3.78 (s, 2H), 3.66 (s, 2H); ¹³C NMR (126 MHz, CDCl₃) δ 197.52, 138.03, 136.23, 133.35, 131.92, 129.50, 128.65, 128.55, 128.45, 128.43, 128.32, 127.59, 123.21, 86.29, 84.21, 59.58, 58.38, 43.46; HRMS (ESI) calculated for [M+H, C₂₄H₂₂NO]⁺: 340.1696; found: 340.1699.




Supplementary Figure 6. Synthetic procedure of substrate **1m**




1m: (*tert*-butyl (2-oxo-2-phenylethyl) carbamate⁷ was used), white solid, 75% yield. ¹H NMR (500 MHz, CDCl₃) δ 8.04 – 7.98 (m, 2H), 7.60 (t, *J* = 7.4 Hz, 1H), 7.49 (t, *J* = 7.6 Hz, 2H), 7.31 – 7.22 (m, 5H), 5.78 (d, *J* = 8.3 Hz, 1H), 5.56 – 5.48 (m, 1H), 3.04 (dd, *J* = 17.1, 5.8 Hz, 1H), 2.89 (dd, *J* = 17.0, 5.1 Hz, 1H), 1.47 (s, 9H); ¹³C NMR (126 MHz, CDCl₃) δ 197.35, 155.27, 134.88, 133.84, 131.71, 128.93, 128.75, 128.22, 128.07, 123.16, 84.17, 84.12, 80.16, 53.93, 28.45, 24.75; HRMS (ESI) calculated for [M+Na, C₂₂H₂₃NNaO₃]⁺: 372.1570; found: 372.1573.




Supplementary Figure 7. Synthetic procedure of substrate **1n**



1n: To a solution of **S9** (2.0 g, 7.01 mmol, 1.0 equiv) in 15 mL MeCN at 0 °C was added K₂CO₃ (1.07 g, 7.71 mmol, 1.1 equiv) and stirred for 2 h, followed by the addition of 3-bromo-1-phenylpropan-1-one⁷ (1.5 g, 7.01 mmol, 1.0 equiv) in one portion, and stirred for 10 h. The reaction was quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na₂SO₄, filtered, and concentrated under vacuum. The residue was recrystallized with hexane/EtOAc to afford **1n** as white solid (2.6 g, 90%). **1n:** ¹H NMR (500 MHz, CDCl₃) δ 7.98 – 7.92 (m, 2H), 7.85 – 7.77 (m, 2H), 7.59 – 7.52 (m, 1H), 7.48 – 7.40 (m, 2H), 7.31 – 7.18 (m, 5H), 7.11 – 7.05 (m, 2H), 4.44 (s, 2H), 3.71 (t, *J* = 7.1 Hz, 2H), 3.45 (t, *J* = 7.1 Hz, 2H), 2.33 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 198.10, 143.65, 136.47, 135.61, 133.42, 131.53, 129.61, 128.68, 128.45, 128.13, 128.07, 127.83, 122.11, 85.58, 82.31, 42.82, 39.01, 38.57, 21.44; HRMS (ESI) calculated for [M+H, C₂₅H₂₄NO₃S]⁺: 418.1471; found: 418.1465.




1p: Preparation of **1p** was carried out according to a procedure similar to that for the synthesis of **1n** from corresponding β-bromoketone. White solid, 93% yield. **1p:** ¹H NMR (500 MHz, CDCl₃) δ 8.06 – 7.93 (m, 2H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.33 – 7.20 (m, 5H), 7.20 – 7.04 (m, 4H), 4.42 (s, 2H), 3.68 (t, *J* = 7.0 Hz, 2H), 3.43 (t, *J* = 7.0 Hz, 2H), 2.35 (s, 3H). ¹³C NMR (126 MHz, CDCl₃) δ 196.66, 167.02, 164.99, 143.80, 135.62, 133.05 (d, *J* = 3.0 Hz), 131.61, 130.86 (d, *J* = 9.4 Hz), 129.71, 128.57, 128.22, 127.93, 122.16, 85.67, 82.35, 42.92, 39.21, 38.71, 21.53; ¹⁹F NMR (376 MHz, CDCl₃) δ -104.62 (m). HRMS (ESI) calculated for [M+Na, C₂₅H₂₂FNNO₃S]⁺: 458.1197; found: 458.1204.




Supplementary Figure 8. Synthetic procedure of substrate **1o**


4-Methyl-N-(pent-2-yn-1-yl)benzenesulfonamide (S11): Preparations of **S11** were carried out according to procedures similar to that for the synthesis of **S9**. All the physical and spectroscopic data of this compound are in agreement with those reported in the literature.⁸



1o: Preparation of **1o** was carried out according to a procedure similar to that for the synthesis of **1n** from substrate **S11**. **1o**: white solid, 80% yield. ¹H NMR (500 MHz, CDCl₃) δ 7.95 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.76 (d, *J* = 8.3 Hz, 2H), 7.59 – 7.54 (m, 1H), 7.46 (t, *J* = 7.7 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 4.15 (t, *J* = 2.2 Hz, 2H), 3.60 (t, *J* = 7.3 Hz, 2H), 3.39 (t, *J* = 7.3 Hz, 2H), 2.41 (s, 3H), 1.92 (qt, *J* = 7.5, 2.2 Hz, 2H), 0.89 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 198.29, 143.52, 136.61, 135.87, 133.49, 129.51, 128.77, 128.15, 127.93, 87.62, 72.39, 42.64, 38.62, 38.57, 21.60, 13.54, 12.24; HRMS (ESI) calculated for [M+H, C₂₁H₂₃NO₃S]⁺: 370.1471; found: 370.1472.




1q: Preparation of **1q** was carried out according to a procedure similar to that for the synthesis of **1n** from substrate **S11** and corresponding β-bromoketone. **1q**: white solid, 85% yield. ¹H NMR (400 MHz, CDCl₃) δ 7.99 (dd, *J* = 8.7, 5.4 Hz, 2H), 7.75 (d, *J* = 8.2 Hz, 2H), 7.29 (d, *J* = 8.0 Hz, 2H), 7.14 (t, *J* = 8.5 Hz, 2H), 4.14 (s, 2H), 3.59 (t, *J* = 7.2 Hz, 2H), 3.37 (t, *J* = 7.2 Hz, 2H), 2.42 (s, 3H), 1.93 (dd, *J* = 15.1, 7.6 Hz, 2H), 0.90 (t, *J* = 7.5 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 196.79, 167.07, 165.04, 143.61, 135.84, 133.14 (d, *J* = 2.9 Hz), 130.87 (d, *J* = 9.3 Hz), 129.57, 128.65 (d, *J* = 267.4 Hz), 127.97, 116.03, 115.86, 87.68, 72.42, 42.69, 38.76, 38.76, 21.64, 13.58, 12.28; ¹⁹F NMR (376 MHz, CDCl₃) δ -104.69 (m); HRMS (ESI) calculated for [M+Na, C₂₁H₂₂FNNO₃S]⁺: 410.1197; found: 410.1201.




Supplementary Figure 9. Asymmetric nickel-catalyzed reductive cyclization of *N*-alkynones



General Procedure: Ni(cod)₂ (2 μ mol, 1 mol %), (*S,S*)-DI-BIDIME (**L4**, 1 μ mol, 0.5 mol %), and dioxane (0.5 mL) were added to a 5 mL screw-cap vial equipped with a magnetic stirring bar in the glove box. Substrate **1** (0.2 mmol, 1.0 equiv.) was added to the solution in one portion, stirred for 5 mins, followed by the addition of triethylsilane (Et₃SiH, 0.6 mmol, 3.0 equiv.). The vial was closed with a screw-cap, and the resulting mixture was stirred at 25 °C for 12 h. Quenched with saturated sodium bicarbonate (NaHCO₃), extracted with ethyl acetate (EtOAc), washed with saturated NaCl, dried over anhydrous sodium sulfate (Na₂SO₄), filtered, and concentrated under vacuum. The residue was purified by column chromatography (10% petroleum ether/EtOAc) to afford compound **2**.



2a: colorless oil, 98% yield, 99:1 er with **L4** (0.1 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 98/2, 254 nm, 6.8 min (*R*), 10.2 min (*S*). The absolute configuration was assigned by the X-ray structure of **3a** (desilylation product of **2a**). **2a**: $[\alpha]_D^{25} = +23.6$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.75 (d, $J = 8.0$ Hz, 2H), 7.48 (d, $J = 7.4$ Hz, 2H), 7.41 – 7.25 (m, 8H), 7.16 (d, $J = 7.6$ Hz, 2H), 6.45 (s, 1H), 4.38 (d, $J = 14.9$ Hz, 1H), 4.21 (dd, $J = 14.9, 1.8$ Hz, 1H), 3.68 (d, $J = 9.6$ Hz, 1H), 3.44 (d, $J = 9.6$ Hz, 1H), 2.44 (s, 3H), 0.91 (t, $J = 7.9$ Hz, 9H), 0.55 (q, $J = 7.7$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 144.01, 143.98, 142.39, 135.92, 132.59, 129.89, 128.78, 128.59, 128.19, 127.95, 127.75, 127.55, 126.10, 126.10, 83.10, 60.68, 50.56, 21.65, 7.14, 6.25; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{30}\text{H}_{37}\text{NNaO}_3\text{SSi}]^+$: 542.2156; found: 542.2159.




Supplementary Figure 10. HPLC chromatogram of chiral product **2a**




To a solution of **2a** (520 mg, 1.0 mmol, 1.0 equiv.) in THF (10 mL) at 0 °C was added TBAF (1.0 M solution in THF, 1.5 mL, 1.5 equiv.), stirred at 0 °C for 0.5 h. Quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous Na₂SO₄, filtered, and concentrated under vacuum.

The residue was purified by column chromatography (20% petroleum ether/EtOAc) to give compound **3a** as white solid (390 mg, 96%). **3a**: $[\alpha]_D^{25} = +24.5$ ($c = 1.0$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, $J = 8.2$ Hz, 2H), 7.39 – 7.32 (m, 2H), 7.29 – 7.13 (m, 8H), 7.03 (d, $J = 7.4$ Hz, 2H), 6.19 (t, $J = 2.3$ Hz, 1H), 4.40 (dd, $J = 15.0, 2.4$ Hz, 1H), 4.16 (dd, $J = 15.0, 2.5$ Hz, 1H), 3.47 (q, $J = 10.4$ Hz, 2H), 2.42 (s, 1H), 2.32 (s, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 144.03, 142.58, 141.59, 135.64, 132.98, 129.93, 128.76, 128.65, 128.44, 128.01, 127.97, 127.94, 126.61, 126.31, 82.05, 61.50, 50.72, 21.68; HRMS (ESI) calculated for [M+Na, C₂₄H₂₃NNaO₃S]⁺: 428.1291; found: 428.1292.

Crystallization from hexanes/EtOAc (9:1) gave crystals suitable for X-ray crystallographic analysis, which revealed its absolute configuration for the chiral tertiary alcohol **3a** as shown in **Figure 1**.




Supplementary Figure 11. X-ray derived ORTEP representation of **3a** (CCDC1532676 contains the supplementary crystallographic data of **3a**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre)




2b: colorless oil, 87% yield, 98:2 er with **L4** (0.5 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 98/2, 254 nm, 15.4 min (*R*), 24.6 min (*S*).

2b: $[\alpha]_D^{25} = +19.1$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.73 (d, $J = 8.0$ Hz, 2H), 7.43 – 7.26 (m, 7H), 7.15 (d, $J = 7.5$ Hz, 2H), 6.84 (d, $J = 8.6$ Hz, 2H), 6.47 (s, 1H), 4.34 (d, $J = 14.8$ Hz, 1H), 4.18 (d, $J = 14.8$ Hz, 1H), 3.82 (s, 3H), 3.68 (d, $J = 9.5$ Hz, 1H), 3.39 (d, $J = 9.5$ Hz, 1H), 2.43 (s, 3H), 0.90 (t, $J = 7.9$ Hz, 9H), 0.53 (dd, $J = 15.6, 7.7$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 159.01, 143.91, 142.39, 135.96, 135.70, 132.73, 129.87, 128.76, 128.60, 127.89, 127.68, 127.47, 125.53, 113.49, 82.70, 60.30, 55.35, 50.33, 21.64, 7.14, 6.24; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{31}\text{H}_{40}\text{NO}_4\text{SSi}]^+$: 550.2447; found: 550.2431.




Supplementary Figure 12. HPLC chromatogram of chiral product **2b**




2c: colorless oil, 90% yield, 99:1 er with **L4** (0.5 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 98/2, 254 nm, 6.9 min (*R*), 10.6 min (*S*). **2c**: $[\alpha]_D^{25} = +11.9$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.74 (d, $J =$

8.2 Hz, 2H), 7.48 – 7.42 (m, 2H), 7.40 – 7.31 (m, 4H), 7.28 (t, $J = 7.4$ Hz, 1H), 7.15 (d, $J = 7.4$ Hz, 2H), 7.02 – 6.96 (m, 2H), 6.44 (t, $J = 2.3$ Hz, 1H), 4.34 (dd, $J = 14.9, 2.3$ Hz, 1H), 4.21 (dd, $J = 14.9, 2.6$ Hz, 1H), 3.66 (d, $J = 9.6$ Hz, 1H), 3.40 (d, $J = 9.6$ Hz, 1H), 2.44 (s, 3H), 0.89 (t, $J = 7.9$ Hz, 9H), 0.58 – 0.49 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 162.16 (d, $J = 246.4$ Hz), 144.08, 142.13, 139.95 (d, $J = 3.1$ Hz), 135.74, 132.47, 129.91, 128.81, 128.57, 127.91, 127.86 (d, $J = 2.0$ Hz), 127.80, 126.08, 114.98 (d, $J = 21.4$ Hz), 82.63, 60.46, 50.43, 21.62, 7.09, 6.23; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{30}\text{H}_{37}\text{O}_3\text{NFSSi}]^+$: 538.2247; found: 538.2234.




Supplementary Figure 13. HPLC chromatogram of chiral product **2c**




2d: colorless oil, 74% yield, 99:1 er with **L4** (0.5 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 7.2 min (*R*), 9.4 min (*S*). **2d**: $[\alpha]_{\text{D}}^{25} = +11.6$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.73 (d, $J = 8.2$ Hz, 2H), 7.43 – 7.32 (m, 6H), 7.31 – 7.25 (m, 3H), 7.14 (d, $J = 7.4$ Hz, 2H), 6.41 (t, $J = 2.2$ Hz, 1H), 4.35 (dd, $J = 15.0, 2.3$ Hz, 1H), 4.20 (dd, $J = 15.0, 2.6$ Hz, 1H), 3.63 (d, $J = 9.7$ Hz, 1H), 3.40 (d, $J = 9.7$ Hz, 1H), 2.44 (s, 3H), 0.89 (t, $J = 7.9$ Hz, 9H), 0.58 – 0.48 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 144.14, 142.91, 141.98, 135.70, 133.42, 132.43, 129.94,


128.84, 128.59, 128.36, 127.93, 127.51, 126.34, 110.10, 82.69, 60.50, 50.50, 21.67, 7.11, 6.25;
 HRMS (ESI) calculated for $[M+H, C_{30}H_{37}O_3NCISi]^+$: 554.1952; found: 554.1935.




Supplementary Figure 14. HPLC chromatogram of chiral product **2d**




2e: colorless oil, 98% yield, > 99:1 er with **L4** (0.25 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 7.7 min (*R*), 9.0 min (*S*). **2e**: $[\alpha]_D^{25} = +13.4$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.76 (d, $J = 8.1$ Hz, 2H), 7.59 (dd, $J = 19.6, 8.4$ Hz, 4H), 7.41 – 7.33 (m, 4H), 7.32 – 7.27 (m, 1H), 7.15 (d, $J = 7.5$ Hz, 2H), 6.41 (s, 1H), 4.38 (dd, $J = 15.0, 2.0$ Hz, 1H), 4.26 (dd, $J = 15.0, 2.3$ Hz, 1H), 3.65 (d, $J = 9.8$ Hz, 1H), 3.44 (d, $J = 9.8$ Hz, 1H), 2.45 (s, 3H), 0.90 (t, $J = 7.9$ Hz, 9H), 0.61 – 0.51 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 148.77, 144.26, 141.87, 135.57, 132.20, 129.96, 129.70 (q, $J = 32.4$ Hz), 128.86, 128.57, 128.04, 127.98, 126.91, 126.27, 125.21 (q, $J = 3.7$ Hz), 124.21 (q, $J = 272.2$ Hz), 82.87, 60.73, 50.69, 21.61, 7.07, 6.24; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{31}\text{H}_{37}\text{O}_3\text{NF}_3\text{SSi}]^+$: 588.2210; found: 588.2216.




Supplementary Figure 15. HPLC chromatogram of chiral product **2e**




2f: colorless oil, 98% yield, 99:1 er with **L4** (0.25 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 12.3 min (S), 22.3 min (R). **2f**: $[\alpha]_D^{25} = +34.3$ (c = 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.75 (d, *J* = 8.2 Hz, 2H), 7.41 – 7.31 (m, 4H), 7.31 – 7.26 (m, 1H), 7.22 (t, *J* = 8.0 Hz, 1H), 7.18 – 7.13 (m, 2H), 7.13 – 7.09 (m, 1H), 7.02 – 6.97 (m, 1H), 6.84 – 6.80 (m, 1H), 6.44 (t, *J* = 2.3 Hz, 1H), 4.40 (dd, *J* = 14.9, 2.3 Hz, 1H), 4.21 (dd, *J* = 14.9, 2.6 Hz, 1H), 3.81 (s, 3H), 3.64 (d, *J* = 9.7 Hz, 1H), 3.46 (d, *J* = 9.7 Hz, 1H), 2.44 (s, 3H), 0.91 (t, *J* = 7.9 Hz, 9H), 0.56 (q, *J* = 7.6 Hz, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 159.46, 145.83, 143.98, 142.23, 135.91, 132.57, 129.88, 129.19, 128.77, 128.58, 127.93, 127.76, 126.33, 118.47, 112.71, 112.19, 83.14, 60.96, 55.29, 50.63, 21.63, 7.15, 6.26; HRMS (ESI) calculated for [M+H, C₃₁H₄₀NO₄SSi]⁺: 550.2447; found: 550.2432.




Supplementary Figure 16. HPLC chromatogram of chiral product **2f**




2g: colorless oil, 98% yield, 99:1 er with **L4** (0.5 mol%) at 60 °C. Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 12.2 min (*S*), 14.9 min (*R*). **2g**: $[\alpha]_D^{25} = +27.0$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.83 (dd, $J = 7.7, 1.7$ Hz, 1H), 7.79 (d, $J = 8.2$ Hz, 2H), 7.38 (d, $J = 8.0$ Hz, 2H), 7.33 (t, $J = 7.6$ Hz, 2H), 7.26 – 7.20 (m, 2H), 7.08 (d, $J = 7.4$ Hz, 2H), 7.00 (td, $J = 7.6, 0.8$ Hz, 1H), 6.67 (d, $J = 7.9$ Hz, 1H), 6.04 (t, $J = 2.1$ Hz, 1H), 4.63 (dd, $J = 14.1, 2.0$ Hz, 1H), 4.03 (dd, $J = 14.1, 2.9$ Hz, 1H), 3.55 (s, 2H), 3.10 (s, 3H), 2.45 (s, 3H), 0.98 (t, $J = 7.9$ Hz, 9H), 0.79 – 0.63 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 155.26, 144.43, 143.70, 136.67, 132.92, 132.06, 129.62, 128.86, 128.71, 128.49, 128.31, 127.45, 127.33, 124.48, 120.36, 111.05, 82.94, 60.39, 54.33, 51.97, 21.65, 7.30, 6.16; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{31}\text{H}_{40}\text{NO}_4\text{SSi}]^+$: 550.2447; found: 550.2433.




Supplementary Figure 17. HPLC chromatogram of chiral product **2g**




2h: colorless oil, 80% yield, 99:1 er with **L4** (1 mol%) at 80 °C. Enantiomeric ratio was determined by chiral HPLC. Chiralpark OD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 98/2, 254 nm, 13.3 min (*S*), 20.5 min (*R*). **2h**: $[\alpha]_D^{25} = +25.9$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.79 (d, $J = 8.3$ Hz, 2H), 7.61 (d, $J = 8.0$ Hz, 1H), 7.41 – 7.27 (m, 7H), 7.21 (t, $J = 7.4$ Hz, 1H), 7.18 – 7.15 (m, 2H), 7.13 (d, $J = 7.7$ Hz, 2H), 7.09 (s, 1H), 6.44 (t, $J = 3.0$ Hz, 1H), 4.71 (d, $J = 3.0$ Hz, 2H), 3.84 (s, 3H), 2.42 (s, 3H), 1.00 (t, $J = 8.0$ Hz, 9H), 0.62 (q, $J = 8.0$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 144.33, 138.65, 137.12, 137.10, 133.16, 131.54, 130.08, 128.72, 128.02, 127.82, 127.60, 127.00, 126.49, 123.28, 122.38, 120.18, 119.91, 117.53, 109.66, 105.90, 53.17, 33.05, 21.68, 6.71, 5.92; HRMS (ESI) calculated for $[\text{M-OTES}, \text{C}_{27}\text{H}_{25}\text{N}_2\text{O}_2\text{S}]^+$: 441.1637; found: 441.1619.




Supplementary Figure 18. HPLC chromatogram of chiral product **2h**




2i: colorless oil, 94% yield, > 99:1 er with **L4** (1 mol%) at 80 °C. Enantiomeric ratio was determined by chiral HPLC with **3i**, the desilylation product of **2i**. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 80/20, 254 nm, 16.3 min (R), 21.8 min (S). **2i**: $[\alpha]_D^{25} = -40.7$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.74 – 7.69 (m, 2H), 7.41 – 7.35 (m, 2H), 7.33 – 7.26 (m, 3H), 7.18 – 7.14 (m, 2H), 6.45 (t, $J = 2.4$ Hz, 1H), 4.26 (dd, $J = 14.9, 2.8$ Hz, 1H), 4.05 (dd, $J = 14.9, 2.2$ Hz, 1H), 3.82 (d, $J = 10.0$ Hz, 1H), 2.89 (d, $J = 10.0$ Hz, 1H), 2.40 (s, 3H), 0.96 (s, 9H), 0.81 (t, $J = 7.9$ Hz, 9H), 0.46 – 0.28 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 143.93, 140.19, 136.05, 132.24, 129.84, 128.81, 128.65, 127.89, 127.51, 126.77, 86.32, 54.49, 51.48, 39.95, 25.13, 21.62, 7.23, 6.46; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{28}\text{H}_{41}\text{NNaO}_3\text{SSi}]^+$: 522.2469; found: 522.2465.




Supplementary Figure 19. HPLC chromatogram of chiral **3i**, the desilylation product of **2i**



2j: colorless oil, 83% yield, 92:8 er with 1 mol% **L4** at 80 °C. Enantiomeric ratio was determined by chiral HPLC with the desilylation product of **2j**. Chiralpark OD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 85/15, 230 nm, 14.1 min (*R*), 17.8 min (*S*). **2j**: $[\alpha]_D^{25} = +17.1$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.72 (d, $J = 8.2$ Hz, 2H), 7.39 – 7.33 (m, 4H), 7.30 – 7.22 (m, 3H), 5.35 (tt, $J = 7.3, 2.5$ Hz, 1H), 4.13 – 4.06 (m, 1H), 3.85 – 3.79 (m, 1H), 3.48 – 3.41 (m, 2H), 2.46 (s, 3H), 1.99 – 1.91 (m, 2H), 0.93 (t, $J = 7.5$ Hz, 3H), 0.89 (t, $J = 7.9$ Hz, 9H), 0.53 (q, $J = 7.7$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 144.24, 143.87, 140.76, 132.58, 129.80, 129.08, 128.05, 127.95, 127.24, 126.15, 82.18, 62.86, 49.59, 22.77, 21.68, 13.23, 7.15, 6.26; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{26}\text{H}_{38}\text{NO}_3\text{SSi}]^+$: 472.2336; found: 472.2338.




Supplementary Figure 20. HPLC chromatogram of chiral product **2j**




2k: light yellow oil, 19% yield, 98:2 er with **L4** (0.5 mol %). Enantiomeric ratio was determined by chiral HPLC. Chiralpark OD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99.8/0.2, 254 nm, 23.5 min (*R*), 25.4 min (*S*). **2k**: $[\alpha]_D^{25} = +16.3$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.58 – 7.50 (m, 2H), 7.46 – 7.29 (m, 6H), 7.19 (d, $J = 7.8$ Hz, 2H), 6.68 (s, 1H), 4.69 (d, $J = 14.4$ Hz, 1H),


4.46 (d, $J = 14.6$ Hz, 1H), 4.00 (d, $J = 8.3$ Hz, 1H), 3.77 (d, $J = 9.9$ Hz, 1H), 0.94 (t, $J = 7.9$ Hz, 9H), 0.58 (q, $J = 7.9$ Hz, 6H); ^{13}C NMR (126 MHz, cdCl_3) δ 141.21, 139.96, 135.30, 128.97, 128.81, 128.55, 128.32, 128.29, 126.60, 120.28 (q, $J = 323.4$ Hz), 82.99, 60.71, 50.74, 7.13, 6.29; HRMS (EI) calculated for $[\text{M}, \text{C}_{24}\text{H}_{30}\text{NO}_3\text{F}_3\text{SSi}]^+$: 497.1668; found: 497.1670.




Supplementary Figure 20. HPLC chromatogram of chiral product **2k**



2l: colorless oil, 10% yield, > 99:1 er with **L4** (0.5 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark OD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 3.99 min (S), 4.57 min (R). **2l**: $[\alpha]_D^{25} = +36.5$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.66 (d, $J = 7.6$ Hz, 2H), 7.43 – 7.27 (m, 10H), 7.25 – 7.17 (m, 3H), 6.31 (s, 1H), 3.91 (d, $J = 14.6$ Hz, 1H), 3.79 (dd, $J = 34.0, 12.9$ Hz, 2H), 3.64 (d, $J = 14.6$ Hz, 1H), 3.10 (d, $J = 9.5$ Hz, 1H), 2.95 (d, $J = 9.6$ Hz, 1H), 0.98 (t, $J = 7.8$ Hz, 9H), 0.69 (q, $J = 7.2$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 148.42, 147.35, 138.58, 137.48, 128.90, 128.52, 128.41, 128.40, 127.69, 127.22, 126.92, 126.65, 126.36, 125.79, 84.06, 69.54, 60.49, 58.25, 7.36, 6.37; HRMS (ESI) calculated for $[\text{M}+\text{H}]^+$: 456.2717; found: 456.2712.




Supplementary Figure 21. HPLC chromatogram of chiral product **2l**




2n: colorless oil, 95% yield, 90:10 er with **L4** (2 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 10.9 min (R), 15.5 min (S). **2n**: $[\alpha]_D^{25} = -14.9$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.52 (d, $J = 7.8$ Hz, 2H), 7.41 – 7.32 (m, 4H), 7.32 – 7.22 (m, 6H), 7.20 (d, $J = 7.8$ Hz, 2H), 6.85 (s, 1H), 4.35 (d, $J = 12.8$ Hz, 1H), 3.67 – 3.58 (m, 1H), 3.18 (d, $J = 12.8$ Hz, 1H), 3.03 (t, $J = 10.1$ Hz, 1H),

2.67 (d, $J = 13.5$ Hz, 1H), 2.36 (s, 3H), 2.17 – 2.07 (m, 1H), 0.74 (t, $J = 7.9$ Hz, 9H), 0.39 – 0.18 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 143.51, 141.58, 138.51, 136.65, 133.85, 129.63, 129.10, 128.55, 128.52, 128.05, 127.82, 127.40, 127.31, 127.17, 77.32, 45.02, 43.96, 37.82, 21.60, 7.04, 6.38; HRMS (ESI) calculated for $[\text{M}+\text{H}, \text{C}_{31}\text{H}_{40}\text{NO}_3\text{SSi}]^+$: 534.2493; found: 534.2495.




Supplementary Figure 22. HPLC chromatogram of chiral product **2n**




2o: colorless oil, 98% yield, 89:11 er with **L4** (2 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 6.2 min (*R*), 8.1 min (*S*). The absolute configuration was assigned by the X-ray structure of **3o** (desilylation of **2o**). **2o**: $[\alpha]_{\text{D}}^{25} = -18.9$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.59 (d, $J = 8.2$ Hz, 2H), 7.26 – 7.18 (m, 7H), 5.58 (t, $J = 7.4$ Hz, 1H), 3.99 (d, $J = 12.7$ Hz, 1H), 3.43 – 3.37 (m, 1H), 3.21 (d, $J = 12.8$ Hz, 1H), 3.03 (ddd, $J = 12.1, 9.3, 3.1$ Hz, 1H), 2.45 (ddd, $J = 13.3, 6.4, 3.2$ Hz, 1H), 2.35 (s, 3H), 2.11 (dtd, $J = 14.8, 7.4, 3.5$ Hz, 2H), 1.92 (ddd, $J = 13.2, 9.1, 3.9$ Hz, 1H), 0.95 (t, $J = 7.5$ Hz, 3H), 0.67 (t, $J = 7.9$ Hz, 9H), 0.29 – 0.13 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 143.48, 142.37, 135.41, 134.08, 129.67, 129.60, 128.23, 127.76, 127.71, 127.36, 77.19, 44.12,

43.71, 38.17, 21.60, 20.83, 14.34, 7.03, 6.41; HRMS (ESI) calculated for $[M+Na, C_{27}H_{39}NNaO_3SSi]^+$: 508.2312; found: 508.2320.




Supplementary Figure 22. HPLC chromatogram of chiral product **2o**




3o (desilylation of **2o**): Preparations of **3o** were carried out according to procedures same as **3a**. **3o**: white solid; $[\alpha]_D^{25} = -24.8$ ($c = 1.0$, $CHCl_3$); 1H NMR (500 MHz, $CHCl_3$) δ 7.68 (d, $J = 8.1$ Hz, 2H), 7.36 – 7.28 (m, 6H), 7.28 – 7.24 (m, 1H), 5.14 (t, $J = 7.3$ Hz, 1H), 4.16 (d, $J = 13.1$ Hz, 1H), 3.58 (d, $J = 13.1$ Hz, 1H), 3.52 – 3.44 (m, 1H), 3.17 (td, $J = 11.7, 2.8$ Hz, 1H), 2.44 (s, 3H), 2.39 – 2.31 (m, 1H), 2.17 – 1.99 (m, 2H), 1.84 – 1.79 (m, 1H), 1.78 (s, 1H), 0.90 (t, $J = 7.5$ Hz, 3H); ^{13}C NMR (126 MHz, $CHCl_3$) δ 143.74, 143.62, 135.52, 134.02, 131.74, 129.78, 128.22, 127.78, 127.47, 126.35, 77.41, 77.16, 76.91, 75.34, 43.84, 42.90, 38.79, 21.63, 20.78, 13.96; HRMS (ESI) calculated for $[M+H, C_{21}H_{26}NO_3S]^+$: 372.1628; found: 372.1629.


Crystallization from hexanes/DCM (9:1) gave crystals suitable for X-ray crystallographic analysis, which revealed its absolute configuration for the chiral tertiary alcohol **3o** as shown in **Figure 2**.




Supplementary Figure 23. X-ray derived ORTEP representation of **3o**. (CCDC1532677 contains the supplementary crystallographic data of **3a**. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre)



2p: colorless oil, 96% yield, 90:10 er with **L4** (2 mol %). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 11.6 min (*R*), 20.5 min (*S*). **2p**: $[\alpha]_D^{25} = -28.5$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.51 (d, $J = 8.2$ Hz, 2H), 7.41 – 7.16 (m, 9H), 6.98 (t, $J = 8.6$ Hz, 2H), 6.83 (s, 1H), 4.33 (d, $J = 12.8$ Hz, 1H), 3.60 (dd, $J = 11.0, 5.0$ Hz, 1H), 3.14 (d, $J = 12.8$ Hz, 1H), 2.99 (t, $J = 10.2$ Hz, 1H), 2.62 (ddd, $J = 13.4, 5.2, 3.1$ Hz, 1H), 2.37 (s, 3H), 2.18 – 2.08 (m, 1H), 0.75 (t, $J = 7.9$ Hz, 9H), 0.39 – 0.20 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 163.35, 161.38, 143.62, 138.37, 137.62 (d, $J = 3.2$ Hz), 136.45, 133.62, 129.66, 129.21 (d, $J = 8.0$ Hz), 128.59, 127.82, 127.34 (d, $J = 12.3$ Hz), 115.45, 115.28, 44.98, 43.92, 37.90, 21.61, 7.02, 6.41; ^{19}F NMR (376 MHz, cdCl_3) δ -114.20 (m); HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{31}\text{H}_{38}\text{FNNaO}_3\text{SSi}]^+$: 574.2218; found: 574.2224.




Supplementary Figure 24. HPLC chromatogram of chiral product **2p**




2q: colorless oil, 98% yield, 89:11 er with **L4** (2 mol%). Enantiomeric ratio was determined by chiral HPLC. Chiralpark AD-H, 25 °C, flow rate: 1 mL/min, hexanes/isopropanol: 99/1, 254 nm, 8.7 min (*R*), 12.7 min (*S*). **2q**: $[\alpha]_D^{25} = -26.9$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.61 (d, $J = 8.0$ Hz, 2H), 7.34 – 7.17 (m, 4H), 6.92 (t, $J = 8.6$ Hz, 2H), 5.58 (t, $J = 7.4$ Hz,

1H), 3.99 (d, $J = 12.7$ Hz, 1H), 3.47 – 3.36 (m, 1H), 3.20 (d, $J = 12.7$ Hz, 1H), 3.02 (dd, $J = 15.0$, 5.9 Hz, 1H), 2.48 – 2.32 (m, 4H), 2.18 – 2.07 (m, 2H), 1.96 (ddd, $J = 13.0$, 10.4, 5.9 Hz, 1H), 0.97 (t, $J = 7.5$ Hz, 3H), 0.69 (t, $J = 7.9$ Hz, 9H), 0.39 – 0.10 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 163.14, 161.18, 143.55, 138.30 (d, $J = 3.2$ Hz), 135.36, 133.81, 129.66, 129.10 (d, $J = 8.0$ Hz), 127.72, 115.01 (d, $J = 21.1$ Hz), 76.72, 44.04, 43.63, 38.18, 21.55, 20.78, 14.27, 6.96, 6.38; ^{19}F NMR (376 MHz, CDCl_3) δ –114.82 (m); HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{27}\text{H}_{38}\text{FNNaO}_3\text{SSi}]^+$: 526.2218; found: 526.2220.




Supplementary Figure 25. HPLC chromatogram of chiral product **2q**


Synthetic Applications



Supplementary Figure 26. Gram-scale reaction and further transformation of cyclization product **2a**




2a (gram scale): To a stirred yellow solution of $\text{Ni}(\text{cod})_2$ (0.682 mg, 2.48 μmol , 0.1 mol%), **L4** (0.816 mg, 1.24 μmol , 0.05 mol%) in dioxane (3 mL) in a 10 mL screw-cap vial, were added alkyne **1a** (1.0 g, 2.48 mmol, 1.0 equiv.) in the glove box. The resulting brown solution was stirred for 15 mins, followed by the addition of triethylsilane (Et_3SiH , 1.19 mL, 7.44 mmol, 3.0 equiv.). The vial was closely sealed, and the resulting mixture was stirred at 60 °C for 12 h. Quenched with saturated sodium bicarbonate (NaHCO_3), extracted with ethyl acetate (EtOAc), washed with saturated NaCl , dried over anhydrous sodium sulfate (Na_2SO_4), filtered, and concentrated under vacuum. The residue was purified by column chromatography (10% petroleum ether/ EtOAc) to afford compound **2a** as colorless oil (1.26 g, 98% yield, 99:1 er). All physical and spectroscopic data of this compound matched those mentioned above.



4a (dr = 7:1): To a solution of **2a** (104 mg, 0.2 mmol, 1.0 equiv.) in MeOH/EA (1:1, 4 mL) was added 10% Pd/C (22 mg, 0.02 mmol, 0.1 equiv.) in one portion. The reaction flask was degassed and purged with hydrogen three times. The reaction mixture was stirred under hydrogen (1 atm) for 24


h, then filtered over a plug of silica gel topped with Celite (MeOH eluent), concentrated to afford white solid as analytically pure which was used without further purification (99% yield, dr = 7:1).

4a: R_f = 0.6 (silica gel, EtOAc/Hexanes 1:9); [α]_D²⁵ = -20.7 (c = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 8.2 Hz, 2H, minor), 7.64 (d, *J* = 8.2 Hz, 2H, major), 7.31 – 7.04 (m, 10H, major + minor), 6.82 (d, *J* = 6.9 Hz, 2H, major), 6.77 (d, *J* = 7.0 Hz, 2H, minor), 3.74 (dd, *J* = 137.7, 10.4 Hz, 2H, minor), 3.68 (dd, *J* = 85.9, 10.9 Hz, 2H, major), 3.45 (dd, *J* = 9.9, 6.4 Hz, 1H, minor), 3.28 (dd, *J* = 10.1, 7.5 Hz, 1H, major), 3.15 (t, *J* = 9.8 Hz, 1H, major), 3.05 (dd, *J* = 9.9, 5.2 Hz, 1H, minor), 2.58 (dd, *J* = 13.9, 3.5 Hz, 1H, major + minor), 2.39 (s, 3H, major), 2.33 (s, 3H, minor), 2.38 (dd, *J* = 13.8, 3.4 Hz, major + minor), 2.07 (qd, *J* = 11.0, 3.6 Hz, 1H, major + minor), 0.85 (t, *J* = 7.9 Hz, 9H, major), 0.71 (t, *J* = 7.9 Hz, 9H, minor), 0.58 – 0.45 (m, 3H, major), 0.34 – 0.21 (m, 1H, minor); ¹³C NMR (126 MHz, CDCl₃) δ 143.67 (major + minor), 142.71 (major + minor), 139.98 (major), 139.71 (minor), 134.93(minor), 134.51(major), 129.87 (major + minor), 128.70 (minor), 128.62 (major), 128.53 (major), 128.43 (minor), 128.35 (major), 128.12 (minor), 127.60, 127.56, 127.50, 126.70, 126.28 (minor), 126.22 (major), 125.52 (major + minor), 83.87 (minor), 83.77 (major), 59.87 (major), 56.85 (minor), 54.47 (major), 53.03 (minor), 51.76 (major), 50.30 (minor), 35.03 (minor), 32.33 (major), 21.69 (major + minor), 7.26 (major), 6.99 (minor), 6.47 (major), 6.17 (minor); HRMS (ESI) calculated for [M+Na, C₃₀H₃₉NNaO₃SSi]⁺: 544.2312; found: 544.2318.




Deprotection of 4a: To a solution of **4a** (dr = 7:1, 52 mg, 0.1 mmol, 1.0 equiv.) in THF (2 mL) at 0 °C was added TBAF (1.0 M solution in THF, 0.15 ml, 1.5 equiv.), stirred at 0 °C for 0.5 h. Quenched with water, extracted with EtOAc, washed with saturated brine, dried with anhydrous

Na₂SO₄, filtered, and concentrated under vacuum. The residue was purified by column chromatography (20% petroleum ether/EtOAc) to give compound **5a** (34.2 mg, 0.084 mmol, 84% yield) and its diastereoisomer **5a'** (4.9 mg, 0.084 mmol, 12% yield) as white solids.




Hydrogenation of 3a: To a solution of **3a** (81 mg, 0.2 mmol, 1.0 equiv.) in MeOH/EA (1:1, 4 mL) was added 10% Pd/C (22 mg, 0.02 mmol, 0.1 equiv.) in one portion. The reaction flask was degassed and purged with hydrogen three times.


The reaction mixture was stirred under hydrogen (1 atm) for 24 h, then filtered over a plug of silica gel topped with Celite (MeOH eluent), concentrated under vacuum. The residue was purified by column chromatography (20% petroleum ether/EtOAc) to give compound **5a** (31.8 mg, 0.78 mmol, 39% yield) and its diastereoisomer **5a'** (48.9 mg, 1.2 mmol, 60% yield) as white solids.



5a: $R_f = 0.3$ (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25} = -19.3$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.70 (d, $J = 8.0$ Hz, 2H), 7.53 – 7.10 (m, 10H), 6.97 (d, $J = 7.6$ Hz, 2H), 3.59 (dd, $J = 41.3, 11.5$ Hz, 2H), 3.50 (t, $J = 8.5$ Hz, 1H), 3.29 (t, $J = 10.1$ Hz, 1H), 2.65 – 2.48 (m, 2H), 2.44 (s, 3H), 2.08 – 1.90 (m, 1H), 1.65 (t, $J = 6.5$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 143.75, 140.43, 139.54, 134.26, 129.89, 128.74, 128.68, 128.49, 127.91, 127.62, 126.45, 125.20, 110.11, 81.36, 62.99, 51.83, 51.46, 31.93, 21.72; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{24}\text{H}_{25}\text{NNaO}_3\text{S}]^+$: 447; found: 430.1450.




5a': $R_f = 0.2$ (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25} = -24.9$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.73 (d, $J = 8.0$ Hz, 2H), 7.34 (dd, $J = 17.6, 5.2$ Hz, 7H), 7.19 (dt, $J = 19.1, 7.7$ Hz, 3H), 6.89 (d, $J = 7.4$ Hz, 2H), 4.07 (d, $J = 10.6$ Hz, 1H), 3.57 (d, $J = 10.6$ Hz, 1H), 3.48 (dd, $J = 9.5, 6.9$ Hz, 1H), 3.22 (dd, $J = 9.8, 3.8$ Hz, 1H), 2.57 – 2.49 (m, 1H), 2.47 – 2.30 (m, 4H), 2.03 (dd, $J = 6.0, 3.4$ Hz, 1H), 1.76 (t, $J = 12.9$ Hz, 1H). ^{13}C NMR (126 MHz, CDCl_3) δ 143.70, 140.53, 139.24, 134.30, 129.87, 128.89, 128.79, 128.63, 128.46, 127.64, 126.45, 126.09, 82.31, 57.73, 51.25, 50.71, 35.66, 21.69; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{24}\text{H}_{25}\text{NNaO}_3\text{S}]^+$: 430.1447; found: 430.1447.




6a: A solution of **2a** (260 mg, 0.5 mmol) in CH_2Cl_2 (10 mL) was treated with a stream of ozone (O_3) at -78°C for 15 mins until the starting material was disappeared on TLC. The excess ozone was purged from the solution with a stream of oxygen (O_2) and Me_2S (1 mL) was added. The reaction was allowed to warm slowly to room temperature, at which point it was diluted with water (10 mL). The subsequent mixture was extracted with CH_2Cl_2 (3×10 mL). The combined organic layers

were washed with brine, dried (Na₂SO₄), filtered, evaporated and purified by flash chromatography on silica gel eluting with petroleum hexanes/ethyl acetate (15:1) to provided compound **6a** as colorless oil (200 mg, 0.45 mmol, 90% yield). **6a**: R_f = 0.8 (silica gel, EtOAc/Hexanes 1:9); [α]_D²⁵ = -18.9 (c = 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, *J* = 8.3 Hz, 2H), 7.50 (dd, *J* = 7.9, 1.7 Hz, 2H), 7.41 – 7.31 (m, 5H), 4.22 (d, *J* = 10.1 Hz, 1H), 3.80 (dd, *J* = 17.9, 0.6 Hz, 1H), 3.47 (d, *J* = 17.8 Hz, 1H), 3.31 (d, *J* = 10.1 Hz, 1H), 2.46 (s, 2H), 0.79 (t, *J* = 7.9 Hz, 9H), 0.39 (qd, *J* = 7.9, 2.8 Hz, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 206.25, 144.61, 137.72, 131.24, 130.00, 128.88, 128.69, 127.93, 126.26, 80.89, 57.18, 51.91, 21.59, 6.67, 5.83; HRMS (ESI) calculated for [M+Na, C₂₃H₃₁NNaO₄SSi]⁺: 468.1635; found: 468.1637.




7a: (desilylation of **6a**): Preparation of **7a** was carried out according to procedure same as **3a**. **7a**: white solid; **6a**: R_f = 0.2 (silica gel, EtOAc/Hexanes 1:9); [α]_D²⁵ = -24.6 (c = 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.72 (d, *J* = 8.1 Hz, 2H), 7.51 – 7.44 (m, 2H), 7.38 (d, *J* = 6.4 Hz, 5H), 4.22 (d, *J* = 10.3 Hz, 1H), 3.94 (d, *J* = 18.1 Hz, 1H), 3.56 (d, *J* = 18.1 Hz, 1H), 3.37 (d, *J* = 10.4 Hz, 1H), 3.25 (bs, 1H), 2.45 (d, *J* = 12.6 Hz, 3H); ¹³C NMR (126 MHz, CDCl₃) δ 207.79, 144.70, 137.35, 131.43, 130.09, 129.10, 129.04, 127.91, 125.44, 79.45, 57.04, 52.12, 21.60; HRMS (ESI) calculated for [M+Na, C₁₇H₁₇NNaO₄S]⁺: 354.0770; found: 354.0773.




8a: To a stirred slurry of CH₃PPh₃Br (475 mg, 1.32 mmol, 3.3 equiv.) in THF (10 mL) were added n-BuLi (2.5 M solution in THF, 0.48 mL, 1.2 mmol, 3.0 equiv.) at -78 °C. The resulting mixture was stirred at -78 °C for 1h, followed by dropwise addition of a solution of **6a** (178 mg, 0.4 mmol, 1.0 equiv.) in THF (2 mL) at this temperature. The mixture was stirred for another 1h at -78 °C, then slowly warmed to 25 °C and kept for 5 h before quenched with Sat.aq NH₄Cl (10 mL). The layer was separated and extracted with EtOAc (3 × 10 mL). The combined organic layers were dried (Na₂SO₄), concentrated and purified by flash chromatography eluting with hexanes /ethyl acetate (19:1) to yield compound **8a** as colorless oil (151 mg, 0.34 mmol, 85% yield). **8a**: R_f = 0.4 (silica gel, EtOAc/hexanes 1:19); [α]_D²⁵ = -21.8 (c = 1.0, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 8.1 Hz, 2H), 7.38 (d, *J* = 7.4 Hz, 2H), 7.32 (d, *J* = 8.0 Hz, 2H), 7.29 – 7.22 (m, 3H), 5.09 (d, *J* = 27.2 Hz, 2H), 4.00 (d, *J* = 14.1 Hz, 1H), 3.87 (d, *J* = 14.0 Hz, 1H), 3.67 (d, *J* = 9.6 Hz, 1H), 3.35 (d, *J* = 9.6 Hz, 1H), 2.43 (s, 3H), 0.83 (t, *J* = 7.9 Hz, 9H), 0.57 – 0.34 (m, 6H); ¹³C NMR (101


MHz, CDCl₃) δ 150.29, 143.84, 143.23, 132.52, 129.74, 128.05, 127.86, 127.48, 125.85, 110.14, 81.44, 60.98, 51.20, 21.58, 6.96, 6.10; HRMS (ESI) calculated for [M+Na, C₂₄H₃₃NNaO₃SSi]⁺: 466.1843; found: 466.1846.




Supplementary Figure 27. Synthetic applications to intermediates of proline and (-)-paroxetine




11: Preparation of **11** was carried out according to procedure same as **6a**. **11**: colorless oil, 90% yield, R_f = 0.8 (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25}$ = -18.4 (c = 1.0, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, J = 7.2 Hz, 2H), 7.31 (d, J = 6.7 Hz, 5H), 7.21 (dd, J = 6.1, 1.7 Hz, 2H), 3.94 (d, J = 14.9 Hz, 1H), 3.68 (d, J = 14.9 Hz, 1H), 3.52 (dt, J = 10.6, 5.3 Hz, 1H), 3.19 (dd, J = 15.1, 6.0 Hz, 1H), 2.67 – 2.52 (m, 1H), 2.44 (d, J = 13.5 Hz, 3H), 2.24 (ddd, J = 9.3, 6.7, 3.0 Hz, 1H), 0.73 (td, J = 7.8, 0.9 Hz, 9H), 0.43 – 0.24 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 201.73, 144.25, 139.07, 133.10, 130.01, 128.72, 128.68, 127.79, 126.98, 80.34, 54.21, 42.71, 38.03, 21.65, 6.92, 6.23; HRMS (ESI) calculated for [M+Na, C₂₄H₃₃NNaO₄SSi]⁺: 482.1792; found: 482.1790.




12: Preparation of **12** was carried out according to procedure same as **8a**. **12**: colorless oil, 88% yield, $R_f = 0.6$ (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25} = -31.3$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.69 – 7.58 (m, 2H), 7.34 – 7.21 (m, 7H), 5.19 (s, 2H), 3.96 (d, $J = 12.4$ Hz, 1H), 3.59 – 3.43 (m, 1H), 3.24 (d, $J = 12.3$ Hz, 1H), 3.05 (t, $J = 10.7$ Hz, 1H), 2.59 – 2.49 (m, 1H), 2.39 (s, 3H), 2.07 – 1.92 (m, 1H), 0.71 (td, $J = 7.9, 1.6$ Hz, 9H), 0.33 – 0.18 (m, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 145.67, 143.47, 141.08, 133.74, 129.57, 128.25, 127.90, 127.69, 127.13, 113.61, 50.62, 43.82, 37.31, 21.47, 6.84, 6.21; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{25}\text{H}_{35}\text{NNaO}_3\text{SSi}]^+$: 480.1999; found: 480.2003.



13: Preparation of **13** was carried out according to similar procedure as **3a**. **13**: white solid; 96% yield, $R_f = 0.2$ (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25} = -36.1$ ($c = 1.0$, CHCl_3); ^1H NMR (400 MHz, CDCl_3) δ 7.67 (d, $J = 8.2$ Hz, 2H), 7.37 – 7.26 (m, 7H), 5.11 (s, 1H), 4.71 (s, 1H), 3.89 (d, $J = 12.6$ Hz, 1H), 3.69 (d, $J = 12.7$ Hz, 1H), 3.44 (dt, $J = 9.4, 4.1$ Hz, 1H), 3.25 – 3.11 (m, 1H), 2.51 – 2.33 (m, 4H), 1.93 (s, 1H), 1.83 (ddd, $J = 13.9, 4.9, 3.1$ Hz, 1H); ^{13}C NMR (126 MHz, CDCl_3) δ 145.16, 143.64, 142.75, 133.60, 129.72, 128.26, 127.77, 127.65, 126.08, 115.20, 74.60, 50.17, 43.00, 38.32, 21.55; HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{19}\text{H}_{21}\text{NNaO}_3\text{S}]^+$: 366.1134; found: 366.1141.




14: Preparation of **14** was carried out according to procedure same as **6a**. **14**: colorless oil, 92% yield, $R_f = 0.8$ (silica gel, EtOAc/Hexanes 1:9); $[\alpha]_D^{25} = -24.1$ ($c = 1.0$, CHCl_3); ^1H NMR (500 MHz, CDCl_3) δ 7.62 (d, $J = 8.1$ Hz, 2H), 7.32 (d, $J = 8.1$ Hz, 2H), 7.19 (dd, $J = 8.6, 5.3$ Hz, 2H), 7.00 (t, $J = 8.5$ Hz, 2H), 3.80 (dd, $J = 78.6, 14.9$ Hz, 2H), 3.48 – 3.38 (m, 1H), 3.26 (ddd, $J = 12.1, 8.3, 3.9$ Hz, 1H), 2.54 (ddd, $J = 14.2, 6.7, 4.0$ Hz, 1H), 2.43 (d, $J = 8.3$ Hz, 3H), 2.34 – 2.20 (m, 1H), 0.79 – 0.63 (m, 9H), 0.33 (qd, $J = 15.1, 7.5$ Hz, 6H); ^{13}C NMR (126 MHz, CDCl_3) δ 201.31, 163.70, 161.72, 144.36, 135.08 (d, $J = 3.4$ Hz), 132.89, 130.03, 128.92 (d, $J = 8.2$ Hz), 127.81, 115.57 (d, $J = 21.5$ Hz), 79.59, 53.95, 42.48, 37.97, 21.66, 6.90, 6.24; ^{19}F NMR (376 MHz, CDCl_3) δ -112.91 (m); HRMS (ESI) calculated for $[\text{M}+\text{Na}, \text{C}_{24}\text{H}_{32}\text{FNNaO}_4\text{SSi}]^+$: 500.1698; found: 500.1709.



15: Preparation of **15** was carried out according to procedure same as **8a**.

15: colorless oil, 86% yield, $R_f = 0.6$ (silica gel, EtOAc/Hexanes 1:9);



$[\alpha]_D^{25} = -53.3$ ($c = 1.0$, CHCl₃); ¹H NMR (500 MHz, CDCl₃) δ 7.63 (d, $J = 7.7$ Hz, 2H), 7.29 (t, $J = 6.2$ Hz, 4H), 6.97 (t, $J = 8.2$ Hz, 2H), 5.18 (d, $J = 9.8$ Hz, 2H), 3.95 (d, $J = 12.4$ Hz, 1H), 3.57 – 3.41 (m, 1H), 3.21 (d, $J = 12.4$ Hz, 1H), 3.01 (dd, $J = 15.5, 5.9$ Hz, 1H), 2.54 – 2.47 (m, 1H), 2.41 (s, 3H), 2.01 (ddd, $J = 13.4, 9.8, 3.6$ Hz, 1H), 0.72 (t, $J = 7.9$ Hz, 9H), 0.34 – 0.18 (m, 6H); ¹³C NMR (126 MHz, CDCl₃) δ 163.37, 161.40, 145.70, 143.69, 137.29 (d, $J = 3.3$ Hz), 133.73, 129.74, 129.10 (d, $J = 8.1$ Hz), 127.85, 115.23 (d, $J = 21.2$ Hz), 113.88, 76.39, 50.67, 43.89, 37.56, 21.63, 6.96, 6.38; ¹⁹F NMR (376 MHz, CDCl₃) δ –114.35 (m); HRMS (ESI) calculated for $[M+Na, C_{25}H_{34}FNNaO_3SSi]^+$: 498.1905; found: 498.1908.




16: Preparation of **16** was carried out according to similar procedure as **3a**.


16: white solid; 96% yield, $R_f = 0.2$ (silica gel, EtOAc/Hexanes 1:9);



$[\alpha]_D^{25} = -46.9$ ($c = 1.0$, CHCl₃); ¹H NMR (400 MHz, CDCl₃) δ 7.65 (d, $J = 8.2$ Hz, 2H), 7.37 – 7.23 (m, 4H), 6.99 (t, $J = 8.7$ Hz, 2H), 5.11 (s, 1H), 4.69 (s, 1H), 3.87 (d, $J = 12.7$ Hz, 1H), 3.66 (d, $J = 12.7$ Hz, 1H), 3.52 – 3.35 (m, 1H), 3.23 – 3.08 (m, 1H), 2.43 (s, 3H), 2.32 (ddd, $J = 14.2, 10.3, 4.2$ Hz, 1H), 1.97 (s, 1H), 1.82 (ddd, $J = 13.9, 4.7, 3.1$ Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 163.35, 160.90, 145.12, 143.77, 138.63 (d, $J = 3.2$ Hz), 133.44, 129.77, 127.97 (d, $J = 8.0$ Hz), 127.78, 115.25 (d, $J = 14.4$ Hz), 114.96, 74.32, 50.11, 42.98, 38.52, 21.57; ¹⁹F NMR (376 MHz, CDCl₃) δ –114.98 (m); HRMS (ESI) calculated for $[M+Na, C_{19}H_{20}FNNaO_3S]^+$: 384.1040; found: 384.1046.






Supplementary Figure 28. ¹H, ¹³C and ³¹P NMR spectra for compound S2








Supplementary Figure 29. ¹H, ¹³C and ³¹P NMR spectra for compound S4




Supplementary Figure 30. ¹H, ¹³C and ³¹P NMR spectra for compound S5








Supplementary Figure 31. ¹H, ¹³C and ³¹P NMR spectra for compound S6






Supplementary Figure 32. ^1H , ^{13}C and ^{31}P NMR spectra for compound S7






Supplementary Figure 33. ^1H , ^{13}C and ^{31}P NMR spectra for compound **S8**









Supplementary Figure 34. ¹H, ¹³C and ³¹P NMR spectra for compound (S,S)-DI-BIDIME (L4)





Supplementary Figure 35. ¹H NMR spectra for compound S9





Supplementary Figure 36. ¹H and ¹³C NMR spectra for compound 1a





Supplementary Figure 37. ¹H and ¹³C NMR spectra for compound **1b**





Supplementary Figure 38. ¹H and ¹³C NMR spectra for compound **1c**





Supplementary Figure 39. ¹H and ¹³C NMR spectra for compound **1d**





Supplementary Figure 40. ¹H and ¹³C NMR spectra for compound 1e





Supplementary Figure 41. ¹H and ¹³C NMR spectra for compound **1f**




Supplementary Figure 42. ¹H and ¹³C NMR spectra for compound **1g**




Supplementary Figure 43. ¹H and ¹³C NMR spectra for compound **1h**





Supplementary Figure 44. ¹H and ¹³C NMR spectra for compound 1i





Supplementary Figure 45. ¹H and ¹³C NMR spectra for compound **1j**





Supplementary Figure 46. ¹H and ¹³C NMR spectra for compound S10





Supplementary Figure 47. ¹H and ¹³C NMR spectra for compound 1k





Supplementary Figure 48. ¹H and ¹³C NMR spectra for compound 11




Supplementary Figure 49. ¹H and ¹³C NMR spectra for compound 1m





Supplementary Figure 50. ¹H and ¹³C NMR spectra for compound 1n








Supplementary Figure 51. ¹H, ¹³C and ¹⁹F NMR spectra for compound **1p**







Supplementary Figure 52. ¹H and ¹³C NMR spectra for compound **1o**







Supplementary Figure 53. ¹H, ¹³C and ¹⁹F NMR spectra for compound **1q**





Supplementary Figure 54. ¹H and ¹³C NMR spectra for compound **2a**





Supplementary Figure 55. ¹H and ¹³C NMR spectra for compound 3a





Supplementary Figure S6. ¹H and ¹³C NMR spectra for compound **2b**




Supplementary Figure 57. ¹H and ¹³C NMR spectra for compound 2c





Supplementary Figure 58. ¹H and ¹³C NMR spectra for compound 2d





Supplementary Figure 59. ¹H and ¹³C NMR spectra for compound **2e**





Supplementary Figure 60. ¹H and ¹³C NMR spectra for compound **2f**




Supplementary Figure 61. ¹H and ¹³C NMR spectra for compound **2g**




Supplementary Figure 62. ¹H and ¹³C NMR spectra for compound 2h




Supplementary Figure 63. ¹H and ¹³C NMR spectra for compound **2i**





Supplementary Figure 64. ¹H and ¹³C NMR spectra for compound 2j




Supplementary Figure 65. ¹H and ¹³C NMR spectra for compound 2k





Supplementary Figure 66. ¹H and ¹³C NMR spectra for compound 2I





Supplementary Figure 67. ¹H and ¹³C NMR spectra for compound 2n




Supplementary Figure 68. ¹H and ¹³C NMR spectra for compound 2o





Supplementary Figure 69. ¹H and ¹³C NMR spectra for compound **3o**






Supplementary Figure 70. ¹H, ¹³C and ¹⁹F NMR spectra for compound **2p**







Supplementary Figure 71. ¹H, ¹³C and ¹⁹F NMR spectra for compound **2q**




Supplementary Figure 72. ¹H and ¹³C NMR spectra for compound **4a**




Supplementary Figure 73. ¹H and ¹³C NMR spectra for compound 5a




Supplementary Figure 74. ^1H and ^{13}C NMR spectra for compound **5a'**




Supplementary Figure 75. ¹H and ¹³C NMR spectra for compound 6a





Supplementary Figure 76. ¹H and ¹³C NMR spectra for compound **7a**




Supplementary Figure 77. ¹H and ¹³C NMR spectra for compound **8a**





Supplementary Figure 78. ¹H and ¹³C NMR spectra for compound **11**




Supplementary Figure 79. ^1H and ^{13}C NMR spectra for compound **12**





Supplementary Figure 80. ¹H and ¹³C NMR spectra for compound 13







Supplementary Figure 81. ¹H, ¹³C and ¹⁹F NMR spectra for compound 14





Supplementary Figure 82. ¹H, ¹³C and ¹⁹F NMR spectra for compound 15





Supplementary Figure 83. ^1H , ^{13}C and ^{19}F NMR spectra for compound **16**

Supplementary References

- 1 Tang, W., Capacci, A. G., Wei, X. D., Li, W. J., White, A., Patel, N. D., Savoie, J., Gao, J. J., Rodriguez, S., Qu, B., Haddad, N., Lu, B. Z., Krishnamurthy, D., Yee, N. K. & Senanayake, C. H. A general and special catalyst for Suzuki–Miyaura coupling processes. *Angew. Chem. Int. Ed.* **49**, 5879–5883 (2010).
- 2 Bera, K., Sarkar, S., Biswas, S., Maiti, S. & Jana, U. Iron-catalyzed synthesis of functionalized 2H-chromenes via intramolecular alkyne–carbonyl metathesis. *J. Org. Chem.* **76**, 3539–3544 (2011).
- 3 Nieto-Oberhuber, C., Pérez-Galán, P., Herrero-Gómez, E., Lauterbach, T., Rodríguez, C., López, S., Bour, C., Rosellón, A., Cárdenas, D. J. & Echavarren, A. M. Gold(I)-catalyzed intramolecular [4+2] cycloadditions of arylalkynes or 1,3-enynes with alkenes: scope and mechanism. *J. Am. Chem. Soc.* **130**, 269–279 (2008).
- 4 Shen, K., Han, X. & Lu, X. Cationic Pd(II)-catalyzed reductive cyclization of alkyne-tethered ketones or aldehydes using ethanol as hydrogen source. *Org. Lett.* **15**, 1732–1735 (2013).
- 5 Li, X., Chen, M., Xie, X., Sun, N., Li, S. & Liu, Y. Synthesis of multiple-substituted pyrroles via Gold(I)-catalyzed hydroamination/cyclization cascade. *Org. Lett.* **17**, 2984–2987 (2015).
- 6 Egorov, M., Delpech, B., Aubert, G., Cresteil, T., Garcia-Alvarez, M. C., Collin, P. & Marazano, C. A concise formation of N-substituted 3,4-diarylpyrroles – synthesis and cytotoxic activity. *Org. Biomol. Chem.* **12**, 1518–1524 (2014).
- 7 Myers, M. C., Iera, J. A., Bang, J.-k., Hara, T., Saito, S., Zambetti, G. P. & Appella, D. H. A new family of small molecules to probe the reactivation of mutant p53. *J. Am. Chem. Soc.* **127**, 6152–6153 (2005).
- 8 Cassfll, D., Parella, T., Sol, M., Pla-Quintana, A. & Roglans, A. Rhodium-catalyzed [2+2+2] cycloaddition reactions of linear allene-ene-yne to afford fused tricyclic scaffolds: insights into the mechanism. *Chem. Eur. J.* **23**, 14889–14899 (2017).